307750 — Kukjeon Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩287bn
- KR₩302bn
- KR₩122bn
- 40
- 13
- 26
- 11
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,284 | 9,959 | 39,259 | 94,971 | 64,833 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 68.2 | 16,299 | 20,409 | 23,919 | 29,101 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,352 | 39,004 | 76,915 | 142,893 | 123,992 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | 14,473 | 24,026 | 46,118 | 86,060 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 10,352 | 57,802 | 106,989 | 196,097 | 225,102 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.245 | 21,782 | 21,852 | 70,691 | 99,823 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 772 | 25,572 | 23,838 | 104,500 | 128,681 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 9,580 | 32,230 | 83,150 | 91,597 | 96,422 |
Total Liabilities & Shareholders' Equity | 10,352 | 57,802 | 106,989 | 196,097 | 225,102 |
Total Common Shares Outstanding |